<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02270034</url>
  </required_header>
  <id_info>
    <org_study_id>GEINO 1402</org_study_id>
    <nct_id>NCT02270034</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety and Activity of Crizotinib With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma</brief_title>
  <official_title>Phase Ib, Open-label, Multicenter, Dose-escalation Study Followed by an Extension Phase to Evaluate the Safety and Activity of the Combination of Crizotinib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Español de Investigación en Neurooncología</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Grupo Español de Investigación en Neurooncología</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicenter, open-label, phase Ib trial aims to assess the safety and activity and&#xD;
      safety of crizotinib (in combination with radiotherapy and temozolomide) in adult patients&#xD;
      with newly diagnosed glioblastoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 13, 2014</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Actual">October 26, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment safety</measure>
    <time_frame>7 months</time_frame>
    <description>Number of participants with adverse events as a measure of safety and tolerability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recommended dose in phase II</measure>
    <time_frame>7 months</time_frame>
    <description>Based on pharmakinetic analysis by Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity</measure>
    <time_frame>7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Two years</time_frame>
    <description>Time between start of treatment and death</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Glioblastoma Multiforme (Grade IV) of Cerebellum</condition>
  <arm_group>
    <arm_group_label>Cohort crizotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of crizotinib with temozolomide and radiotherapy following Stupp regime</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crizotinib</intervention_name>
    <description>Crizotinib is added to Stupp method</description>
    <arm_group_label>Cohort crizotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
          2. Male or Female ≥18 years old and ≤ 70 years old&#xD;
&#xD;
          3. Newly diagnosed glioblastoma (GB) confirmed by biopsy or resection 4-7 weeks before&#xD;
             registration.&#xD;
&#xD;
          4. Patients must have at least 15 unstained slides or 1 tissue block (frozen or paraffin&#xD;
             embedded) available from a prior biopsy or surgery (archival tumor material).&#xD;
&#xD;
          5. Patients must have sufficient time for recovery from prior surgery (at least 4 weeks).&#xD;
&#xD;
          6. Karnofsky Performance Score (KPS) ≥ 60%.&#xD;
&#xD;
          7. Adequate hematologic function: Hemoglobin ≥ 10 g/dL, Leukocytes &gt; 3,000/mcL, absolute&#xD;
             neutrophil count (UNL) ≥ 1,500 cells/ul, platelets ≥ 100,000 cells/ul.&#xD;
&#xD;
          8. Adequate liver function: Bilirubin ≤ 2 X upper limit of normal (ULN); aspartate&#xD;
             aminotrasferase (AST) (SGOT) ≤ 2.5 X ULN&#xD;
&#xD;
          9. Creatinine within normal institutional limits or creatinine clearance &gt; 60 mL/min/1.73&#xD;
             m2l for subjects with creatinine levels above institutional normal.&#xD;
&#xD;
         10. The effects of crizotinib on the developing human fetus are unknown. For this reason,&#xD;
             women of child-bearing potential and men must agree to use adequate contraception&#xD;
             (hormonal or harrier method of birth control; abstinence; surgical sterilization)&#xD;
             prior to study entry and for the duration of study participation and for at least 3&#xD;
             months thereafter. The definition of effective contraception will be based on the&#xD;
             judgment of the principal investigator or a designated associate. Should a woman&#xD;
             become pregnant or suspect she is pregnant while participating in this study, she&#xD;
             should inform her treating physician immediately. All female patients with&#xD;
             reproductive potential must have a negative pregnancy test (serum/urine) within 2&#xD;
             weeks prior to starting treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of extra-cranial metastatic disease.&#xD;
&#xD;
          2. Any prior radiotherapy (RT) or chemotheraphy (QT) treatment.&#xD;
&#xD;
          3. Patients must not have received prior Gliadel wafers.&#xD;
&#xD;
          4. The use of enzyme-inducing antiepileptic drugs will not be allowed. Those patients&#xD;
             taking enzyme-inducing antiepileptic drugs required a 7-day washout period before&#xD;
             registration.&#xD;
&#xD;
          5. Any surgery (not including minor diagnostic procedures such as lymph node biopsy)&#xD;
             within 2 weeks of baseline disease assessments; or not fully recovered from any side&#xD;
             effects of previous procedures.&#xD;
&#xD;
          6. Any clinically significant gastrointestinal abnormalities, which may impair intake,&#xD;
             transit or absorption of the study drug, such as the inability to take oral medication&#xD;
             in tablet form.&#xD;
&#xD;
          7. Any psychiatric or cognitive disorder that would limit the understanding or rendering&#xD;
             of informed consent and/or compromise compliance with the requirements of this&#xD;
             protocol.&#xD;
&#xD;
          8. Uncontrolled or significant cardiovascular disease, including:&#xD;
&#xD;
               -  A myocardial infarction within 12 months;&#xD;
&#xD;
               -  Uncontrolled angina within 6 months;&#xD;
&#xD;
               -  Congestive heart failure within 6 months;&#xD;
&#xD;
               -  Diagnosed or suspected congenital long QT syndrome;&#xD;
&#xD;
               -  Any history of clinically significant ventricular arrhythmias (such as&#xD;
                  ventricular tachycardia, ventricular fibrillation, or Torsades de pointes);&#xD;
&#xD;
               -  Prolonged corrected QT (QTc) interval on pre-entry electrocardiogram (&gt;470 msec);&#xD;
&#xD;
               -  Any history of second or third degree heart block (may be eligible if currently&#xD;
                  have a pacemaker);&#xD;
&#xD;
               -  Heart rate &lt;50/minute on pre-entry electrocardiogram;&#xD;
&#xD;
               -  Uncontrolled hypertension.&#xD;
&#xD;
          9. Any patient with a history of significant cardiovascular disease, even if currently&#xD;
             controlled, or who has signs or symptoms suggesting impaired left ventricular function&#xD;
             in the judgment of the investigator must have a screening left ventricular ejection&#xD;
             fraction (LVEF) evaluation by ECHO or angyography (MUGA). Patients with LVEF&#xD;
             measurements below local institutional lower limit of normal or less than 50% will not&#xD;
             be eligible.&#xD;
&#xD;
         10. Individuals with a history of a different malignancy are ineligible except for the&#xD;
             following circumstances: Individuals with a history of other malignancies are eligible&#xD;
             if they have been disease-free for at least 3 years and are deemed by the investigator&#xD;
             to be at low risk for recurrence of that malignancy. Individuals with the following&#xD;
             cancers are eligible if diagnosed and treated within the past 3 years: cervical cancer&#xD;
             in situ, and basal cell or squamous cell carcinoma of the skin. Patients will not be&#xD;
             eligible if they have evidence of other malignancy requiring therapy other than&#xD;
             surgery within the last 3 years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan Manuel Sepúlveda, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital 12 de Octubre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>María Martínez, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital del Mar</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Català D'Oncologia L'Hospitalet (Ico)</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 14, 2014</study_first_submitted>
  <study_first_submitted_qc>October 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2014</study_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crizotinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

